209 related articles for article (PubMed ID: 27977325)
1. Guest editor's note: Special issue on biosimilarity assessment.
Chang VY; Endrenyi L
J Biopharm Stat; 2017; 27(2):195-196. PubMed ID: 27977325
[No Abstract] [Full Text] [Related]
2. Special issue of statistical genetics and genomics in clinical trials: guest editor's note.
Wu R; Lin M
J Biopharm Stat; 2010 Mar; 20(2):191-2. PubMed ID: 20309753
[No Abstract] [Full Text] [Related]
3. Guest editor's note: missing data--moving forward.
Soon GG
J Biopharm Stat; 2011 Mar; 21(2):177-9. PubMed ID: 21390994
[No Abstract] [Full Text] [Related]
4. Adjustment for unbalanced sample size for analytical biosimilar equivalence assessment.
Dong XC; Weng YT; Tsong Y
J Biopharm Stat; 2017; 27(2):220-232. PubMed ID: 28060570
[TBL] [Abstract][Full Text] [Related]
5. Frequency estimator for assessing of follow-on biologics.
Lu Y; Zhang ZZ; Chow SC
J Biopharm Stat; 2014; 24(6):1280-97. PubMed ID: 25072640
[TBL] [Abstract][Full Text] [Related]
6. Guest editors' note: Special issue on subgroup analysis in clinical trials.
Wang SJ; Dmitrienko A
J Biopharm Stat; 2014; 24(1):1-3. PubMed ID: 24392974
[No Abstract] [Full Text] [Related]
7. Nonparametric tests for evaluation of biosimilarity in variability of follow-on biologics.
Zhang N; Yang J; Chow SC; Chi E
J Biopharm Stat; 2014; 24(6):1239-53. PubMed ID: 25036940
[TBL] [Abstract][Full Text] [Related]
8. Scientific factors and current issues in biosimilar studies.
Chow SC; Endrenyi L; Lachenbruch PA; Mentré F
J Biopharm Stat; 2014; 24(6):1138-53. PubMed ID: 25098559
[TBL] [Abstract][Full Text] [Related]
9. Comments on the FDA draft guidance on biosimilar products.
Chow SC; Endrenyi L; Lachenbruch PA
Stat Med; 2013 Feb; 32(3):364-9. PubMed ID: 22903309
[TBL] [Abstract][Full Text] [Related]
10. Clinical development and trial design of biosimilar products: a Japanese perspective.
Nagasaki M; Ando Y
J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
[TBL] [Abstract][Full Text] [Related]
11. Guest editors' note: Special issue associated with the 2013 ASA Biopharmaceutical FDA/Industry Statistics Workshop.
Binkowitz B; Yue LQ
J Biopharm Stat; 2014; 24(5):965-7. PubMed ID: 25014118
[No Abstract] [Full Text] [Related]
12. Estimation and approximation approaches for biosimilar index based on reproducibility probability.
Yang LY; Lai CH
J Biopharm Stat; 2014; 24(6):1298-311. PubMed ID: 25033191
[TBL] [Abstract][Full Text] [Related]
13. Sample size requirement in analytical studies for similarity assessment.
Chow SC; Song F; Bai H
J Biopharm Stat; 2017; 27(2):233-238. PubMed ID: 27935446
[TBL] [Abstract][Full Text] [Related]
14. Special issue on active controlled clinical trials: guest editor's note.
Tsong Y
J Biopharm Stat; 2007; 17(2):197-9. PubMed ID: 17365217
[No Abstract] [Full Text] [Related]
15. Sample size calculations for the development of biosimilar products.
Kang SH; Kim Y
J Biopharm Stat; 2014; 24(6):1215-24. PubMed ID: 25032735
[TBL] [Abstract][Full Text] [Related]
16. Guest editors' note for the special issue on the statistical considerations for the design and analysis of bridging and multiregional clinical trials.
Tsong Y; Wang W
J Biopharm Stat; 2012 Sep; 22(5):875-8. PubMed ID: 22946936
[No Abstract] [Full Text] [Related]
17. A note on special articles on adaptive clinical trial designs.
Chow SC
J Biopharm Stat; 2010 Nov; 20(6):1088-9. PubMed ID: 21058103
[No Abstract] [Full Text] [Related]
18. On the glycosylation aspects of biosimilarity.
Hajba L; Szekrényes Á; Borza B; Guttman A
Drug Discov Today; 2018 Mar; 23(3):616-625. PubMed ID: 29337201
[TBL] [Abstract][Full Text] [Related]
19. Note on special technical issue on adaptive designs for clinical trials.
Liu Q; Chang M
J Biopharm Stat; 2012; 22(4):615-6. PubMed ID: 22651104
[No Abstract] [Full Text] [Related]
20. Statistical considerations in biosimilar clinical efficacy trials with asymmetrical margins.
Li Y; Liu Q; Wood P; Johri A
Stat Med; 2013 Feb; 32(3):393-405. PubMed ID: 22991275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
